State Street Corp Satsuma Pharmaceuticals, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$4.19 - $7.95 $80,448 - $152,640	19,200 Added 44.61%	62,236 $373,000
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $27,125 - $38,176	7,176 Added 20.01%	43,036 $164,000
Q4 2021 Feb 14, 2022	BUY	$4.15 - $6.24 $72,417 - $108,888	17,450 Added 94.79%	35,860 $161,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $832,689 - $1.26 Million	-173,477 Reduced 90.41%	18,410 $130,000
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $66,626 - $104,677	14,579 Added 8.22%	191,887 $1.13 Million
Q4 2020 Feb 16, 2021	BUY	$3.56 - $5.09 $57,672 - $82,458	16,200 Added 10.06%	177,308 $817,000
Q3 2020 Nov 10, 2020	BUY	$3.85 - $28.47 $91,930 - $679,806	23,878 Added 17.4%	161,108 $627,000
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $1.09 Million - $2.37 Million	68,269 Added 99.0%	137,230 $3.95 Million
Q1 2020 May 11, 2020	BUY	$14.53 - $30.69 $1 Million - $2.12 Million	68,961 New	68,961 $1.48 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.